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Introduction
The human gastrointestinal tract (GIT) is home to trillions of 
finely tuned, interacting microbes, which are defined as the gut 
microbiota.1 Their combined genomes provide us additional 
functions and molecules.2-4 The phylogeny, age and geographi-
cal origin of a host5 and other factors, such as obesity,6 diet,7 
pregnancy,8 and antibiotic usage,9,10 strongly shape gut microbial 
diversity. The insights gained from a series of studies emphasiz-
ing the contribution of colonic bacteria in modulating the host 
health status (e.g., by participating in liver development and 
in the metabolism of bile acids and hormones) underscore the 
importance of the GIT microbiome for gut homeostasis.10-15
The microbiomes in the gastrointestinal tract (GIT) of individuals receiving antibiotics and those in obese subjects 
undergo compositional shifts, the metabolic effects and linkages of which are not clearly understood. Herein, we set 
to gain insight into these effects, particularly with regard to carbohydrate metabolism, and to contribute to unravel the 
underlying mechanisms and consequences for health conditions. We measured the activity level of GIT carbohydrate-
active enzymes toward 23 distinct sugars in adults patients (n = 2) receiving 14-d β-lactam therapy and in obese (n 
= 7) and lean (n = 5) adolescents. We observed that both 14 d antibiotic-treated and obese subjects showed higher 
and less balanced sugar anabolic capacities, with 40% carbohydrates being preferentially processed as compared with 
non-treated and lean patients. Metaproteome-wide metabolic reconstructions confirmed that the impaired utilization of 
sugars propagated throughout the pentose phosphate metabolism, which had adverse consequences for the metabolic 
status of the GIT microbiota. The results point to an age-independent positive association between GIT glycosidase 
activity and the body mass index, fasting blood glucose and insulin resistance (r2 ≥ 0.95). Moreover, antibiotics altered 
the active fraction of enzymes controlling the thickness, composition and consistency of the mucin glycans. Our data 
and analyses provide biochemical insights into the effects of antibiotic usage on the dynamics of the GIT microbiota 
and pin-point presumptive links to obesity. The knowledge and the hypotheses generated herein lay a foundation for 
subsequent, systematic research that will be paramount for the design of “smart” dietary and therapeutic interventions 
to modulate host-microbe metabolic co-regulation in intestinal homeostasis.
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The richness, diversity and evenness of bacterial taxa and gene 
content of the GIT microbiota have been shown to be altered 
in obese and antibiotic-treated subjects.6,10,16 In humans, long-
term exposure to antibiotics has been associated with weight 
gain and acquired obesity,17,18 and a link between antibiotic use 
and obesity was proposed.19 Indeed, antibiotic treatments have 
long been used to promote weight gain and increase body mass 
index (BMI) in animals.20 While research efforts to elucidate the 
impact of antibiotic treatment and obesity on GIT microbiota 
have mainly focused on community shifts and metagenomic 
data,21,22 little is known about the functional consequences of 
these shifts on the cross-talk between gut microbial metabolism 
and host responses.
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to 81% [for FS-3]) of the total activity) and glucuronidases 
and cellulases (accounting for < 1% of total activity) were the 
most and least active enzymes (table s2), respectively, indepen-
dently of the duration of the treatment. These data agree with 
the generally low fermentability of insoluble fibers such as cel-
luloses and hemicelluloses.26 Note that β-fucose, α-mannose and 
α-arabinopyranose were preferentially hydrolyzed over α-fucose, 
β-mannose and β-arabinopyranose, with altered relative activity 
levels between isomers depending on the time point (fig. 1a; 
table s2). This result contrasted with the overall similar hydro-
lytic capacities for α- and β-xylose, which were not significantly 
affected by the antibiotic therapy.
Third, different trends toward alterations of the metabolism 
of specific carbohydrates, was observed throughout the therapy. 
According to VEGAN package,27 five sugar clusters were evident 
(fig. 2). The hydrolytic capacity for the sugars included in cluster 
one decreased during therapy, reaching a minimum on day 11; 
these sugars included α-glucose, α-maltopentose, α-xylose and 
β-arabinopyranose. For the cluster two, the activity level was 
maximal on days 3 and 14 and minimal on day 11, including 
α- and β-galactose, β-cellobiose and α-arabinofuranose. The 
activities for sugars in cluster three decreased on day 3 but rapidly 
increased to peak on day 14; these activities involved β-glucose, 
β-mannose, β-lactose, β-fucose and α-maltose. In cluster four, 
the activities oscillated, reaching maximum on day 6, includ-
ing β-xylose, β-glucuronide, β-acetylglucuronide, α-rhamnose 
and α-fucose. Finally, α-maltohexose, α-acetylneuraminic acid, 
N-acetyl-β-D-glucosaminide and α-mannose, were the only sug-
ars hydrolyzed at the highest level on day 11; these four carbohy-
drates formed cluster five.
shifts in carbohydrate turnover metabolism between lean 
and obese. We further evaluated the glycosidase activity profiles 
in the fecal microbiota of lean (n = 5) and obese (n = 7) adoles-
cents aged 13–16 y. As regards to the activity values per each 
of the sugars, no statistically significant differences (p < 0.05; 
Student’s t-test) were found between the subsets of each of the 
two groups; same as for P1 and P2, results in figure 1 are pre-
sented as mean values ± standard errors. From the data shown 
in figure 1b, obese subjects were characterized by a higher total 
sugar metabolism capacity, with a net global increase for the 23 
carbohydrate tested from 38.0 ± 0.6 to 426.5 ± 3.2 units/g total 
protein. In addition, in comparison with lean subjects, obese had 
a less balanced GIT biochemical environment with declining rela-
tive activity levels toward α-acetylneuraminic acid (Obese/Lean: 
0.01%/0.26%), N-acetyl-β-d-glucosaminide (0.02%/0.31%), 
β-fucose (1.1%/5.3%), α-arabinopyranose (1.3%/4.0%) and 
α-rhamnose (1.6%/4.2%), while having drastic improvements 
for α-arabinofuranose (11.0%/1.1%) and α-glucose (7.8%/1.4%) 
activities (table s2).
shared and distinct functional changes: antibiotic-treated 
adults vs. obese and lean adolescents. Comparison of the glyco-
sidase activities in obese and antibiotic-treated patients yielded 
two common characteristics. First, a 14 d antibiotic treatment 
promoted the total GIT glycosidase activity (approximately 
3-fold) as compared with the admission day, a trait that was also 
observed albeit at higher level (11-fold) in obese as compared with 
Our recent study in fecal samples from a patient subjected to 
a β-lactam intravenous therapy suggested that antibiotics may 
ultimately alter the energy balance in the GIT.10 A number of 
reports suggest that the relative contribution glycoside-hydro-
lases (GH) or glycosidases is indicative of the capacity for sugar 
metabolism and energy production and conversion in the GIT 
microbiome,23,24 and that its alteration may stimulate weight 
gain.25 Therefore, in the study herein presented, we set to assess 
the functional differences and consequences of microbial shifts 
in the human gastrointestinal tract in relation to antibiotic treat-
ment and obesity. To this end, we systematically collected gly-
cosidase activity data in fecal bacterial proteins from unrelated 
adult patients (n = 2) upon 14 d antibiotic therapy, plus obese 
(n = 7) and lean (n = 5) adolescents who did not present any 
intestinal disorders and had not taken antibiotics (for details see 
table s1). The variations in fecal bacterial glycosidase activities 
were complemented with: (1) a metaproteome-wide integrated 
metabolic analysis to quantify the impact of the activity shifts 
on the GIT metabolism itself; and (2) a comparative analy-
sis between activity levels and anthropometric and biochemi-
cal parameters to find presumptive correlation variables. With 
this joint functional approach we laid a foundation to study 
unto what degree antibiotic use and obesity correlate with the 
acquisition and stability of functional characteristics of the GIT 
microbiota. We believe that future attempts to manipulate gut 
microbiome will capitalize, among other, on the knowledge of 
GH as potential targets to benefit human health through thera-
peutic and dietetic interventions.
Results
shifts in carbohydrate turnover metabolism in antibiotic-
treated patients. figure 1 displays the specific activities (units/g 
total protein), tested against 23 sugars, of the intra-cellular bac-
terial proteins from fecal samples (FS) from patients P1 (68-y-
old male) and P2 (73-y-old female), prior (day 0; FS-0) and on 
days 3 (FS-3), 6 (FS-6), 11 (FS-11) and 14 (FS-14) of β-lactam 
intravenous therapy. As regards to the activity values per each 
of the sugars, P1 and P2 could not be distinguished from each 
other (interpersonal variations ranging from 1.69 × 10−5 to 1.0%, 
depending on the sugar); accordingly, results are presented as 
mean values ± standard errors (fig. 1). There were several notable 
findings.
First, a 2-fold increase in total glycosidase activity occurred 
on day 3 that recovered on days 6 and 11 (fig. 1a, inset), time 
points characterized by a decrease in total bacterial taxa and rich-
ness.10 Interestingly, on day 14, when bacterial community were 
significantly less active at the level of RNA,10 a 3-fold activity 
increase was observed compared with FS-0 (fig. 1a, inset).
Second, the specific activity ratios for the most to least effi-
ciently hydrolyzed carbohydrates were 385 (for FS-6), 410 (for 
FS-11), 496 (for FS-0), 683 (for FS-14) and 3,081 (for FS-3), 
with β- and α-galactose being the most efficiently hydrolyzed 
carbohydrates and β-glucuronide, β-acetylglucuronide and 
β-cellobiose being hydrolyzed at the lowest levels (fig. 1a). 
Accordingly, β-galactosidases (ranging from 47% [for FS-11] 
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the GIT microbiota to metabolize carbohydrates, that is, whether 
a relation between the GIT glycosidase activity (fig. 1) and BMI 
could be established. Results shown in figure 3a provide evi-
dences of the goodness of a sigmoid (r2 = 0.98; BMI
50
 value of 
24) model to adequately describe this dependence for all subjects 
investigated but one (P1). Noteworthy, comparison of the glyco-
sidase activity between adult P2 (weight [Kg], 54.0; BMI [Kg/
m2], 33.5) the admission day prior to the antibiotic treatment 
and the adolescents with similar BMI (weights [Kg], 40.9–65.9; 
BMI [Kg/m2], 17.94–23.57) yielded essentially the same results 
(fig. 3a). As the host fasting glucose and homeostasis model 
assessment-estimated insulin resistance (HOMA-IR) indexes28 
were available for the obese subjects, a similar analysis was per-
formed; we found a linear relation (r2 ≥ 0.94) between both data 
types and GIT glycosidase activity (fig. 3b); note that this cor-
relation was only observed for patients with ≥ 83 mg/dL fasting 
blood glucose. Other biochemical data (table s1) related to host 
lipid and nitrogen metabolisms did not correlate with glycosidase 
activity.
antibiotics promote host mucus hydrolyzing activities when 
richness and biodiversity decrease. The census of GH-like 
enzymes (183 in total from 37 families) in P1 fecal bacte-
rial protein extracts, determined through quantitative shotgun 
lean (fig. 1). Second, nine out of 23 substrates were also preferen-
tially processed in both obese and 14 d antibiotic-treated subjects, 
including α-glucose, β-glucose, α-maltohexose, α-galactose, 
β-galactose, α-arabinopyranose, α-arabinofuranose, α-manose 
and β-fucose (fig. 1 and table s2).
Similarly to antibiotic-treated adult patients, high levels of 
activity toward α- and β-galactose characterized both lean- and 
obese-adolescents and accounted for 32% and 39% of the total 
normalized activity, respectively (fig. 1; table s2). This suggests 
that the Human GIT microbiome is particularly enriched in 
both activities, independently of the subject and the age. By con-
trast, activity toward α-acetylneuraminic acid and N-acetyl-β-d-
glucosaminide accounted for < 0.6% (or < 0.22 ± 0.13 units/g) of 
the total normalized activity in obese and lean subjects as well as 
in patients before the antibiotic treatment (fig. 1; and table s2), 
while their contribution at day 11 of the antibiotic intervention 
accounted for ~12% (or 6.4 ± 0.73 units/g). This indicates that 
both activities play secondary roles in the GIT microbiota in the 
absence of antibiotics, while they become particularly enriched as 
a consequence of the antibiotic treatment.
git glycosidase activity associated with bmi and glu-
cose level. We further evaluated whether subject characteristics 
(table s1) such as BMI may be strong predictor of the capacity of 
Figure 1. Shifts in carbohydrate turnover profile. Enzyme activities (units per gram total protein) from the total faecal microbiota against 23 different 
sugar substrates were quantified by measuring the release of pNP in triplicates, as described in Materials and Methods section. (A) Glycosidase profile 
for both β-lactam-treated adult patients P1 and P2 in the time span investigated. (B) Glycosidase profile for lean (n = 5) and obese (n = 7) adolescents. 
A single plot (with mean values ± SD, estimated for each group of samples using three independent measurements each) is shown for P1/P2 (panel 
A) and lean and obese subjects (panel B), as no statistically significant differences in activity values were discernible within each set of samples. The 
insets in panels (A) and (B) represent the cumulative activity (total units per gram ± SD) for all sugars being hydrolyzed for each of the samples. Note: 
α- and β-galactosidase activities were separated, as the activity levels were significantly higher as compared with the other activities and are shown in 
the left panels.
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available for patient P1,10 into a network model that collected the 
metabolic routes that might be present in the microbiome. These 
network models showing changes in the metabolic reactions are 
shown in figure s2. We observed that compared with FS-0, the 
significant reduction of enzyme expression observed at day 11 
of the antibiotic therapy (fig. 4a) had a direct metabolic conse-
quence: 121 reactions were partially (from 1.5- to 20-fold) and 
47 totally deactivated (table s3), as compared with the begin-
ning of the therapy. A comparison of FS-11 network topolo-
gies, with reduced sugar hydrolysis capacity (fig. 1a) correlated 
with the strong downregulation of reactions linked to glycolysis 
(32-fold) and pentose phosphate (18-fold) pathways compared 
with FS-0 (tables s4 and s5). In addition, the global attenua-
tion of carbohydrate metabolism was followed to a lesser extent 
by changes in amino acid metabolism (tables s4 and s5). Thus, 
in sample FS-11, 7 out of 11 pathways of amino acid metabolism 
metaproteome measurements,10 showed no significant differences 
in GH-like enzymes counts (fig. s1). However, their expres-
sion was, by contrast, greatest on day 11 when the expression 
of other enzymes (193 classes according to their EC numbers) 
was minimal (fig. 4a). This is a result of the high expres-
sion levels of mucin glycan degrading families 2 and 20 β-N-
acetylhexosaminidases (EC 3.2.1.52)29 in FS-11 with respect to 
the level of total GH-like enzymes (fig. 4b) and total enzyme 
content (fig. 4C). This agrees with the fact that FS at day 11 
showed a marked increase of activity against α-acetylneuraminic 
acid and N-acetyl-β-d-glucosaminide (fig. 1). Note that FS-14 
was characterized by the lowest expression of GH-like enzymes 
(fig. 4a), with a major fraction (~16% of the total) expressed at 
levels < 0.2% of the relative concentration (fig. 4b).
metabolic shifts. Using the method described in Materials 
and Methods, we further integrated protein expression data 
Figure 2. Correspondence analysis of the carbohydrate turnover profile. The relative proportion of glycosidase activity (units/g total protein) for each 
of 23 different sugars in the different samples was considered for the analysis. Five distinct clusters (color-coded in the figure), which are based on 
shifts in the turnover profiles toward the different sugars, are evident. Cluster one included α-glucose (S1), α-d-maltopentose (S4), α-xylose (S9) and 
β-arabinopyranose (S12). Cluster two included β-d-cellobiose (S6), α-l-galactose (S7), β-d-galactose (S8) and α-arabinofuranose (S13). Cluster three in-
cluded β-d-glucose (S2), α-maltose (S3), β-d-mannose (S16), β-lactose (S17) and β-fucose (S19). Cluster four included β-xylose (S10), α-l-rhamnose (S14), 
α-fucose (S18), β-glucuronide (S20) and β-acetylglucuronide (S21). Cluster five included α-d-maltohexose (S5), α-mannose (S15), α-acetylneuraminic 
acid (S22) and N-acetyl-β-d-glucosaminide (S23). The mean values for each group of samples were calculated accordingly to data provided in Figure 1.
310 Gut Microbes Volume 4 Issue 4
considerable resilient due to redundancy among its constituent 
taxa, antibiotic perturbation disrupts our microbial ecosystem 
and imprints a long-term selection of new community members 
that possibly deploy or activate species-encoded functional pro-
cesses. This hypothesis is underscored by the fact that β-lactam 
treatment was shown to have marked effects on the capacity to 
anabolize at least 40% of all sugars investigated. Another obser-
vation of the altered functional community was an improvement 
on the mucin “scavenging” capacity when the total biodiversity 
reached a minimum as a consequence of the antibiotic therapy. It 
is plausible that some gut microbial species rely on host glycans 
in the absence of energetic input because of the impaired utili-
zation of dietary carbohydrates and depression of carbohydrate 
metabolism in the GIT at intermediate stages of the antibiotic 
therapy, as has been demonstrated in absence of dietary inputs.31 
Together with previous observations, our findings support the 
hypothesis that antibiotic effects should be significant factors in 
the symptoms related to carbohydrate maldigestion,25,32 and the 
progression of infections and diseases. The fact that the altered 
composition of mucus is likely a key factor in determining which 
microorganisms physically associate with this layer, copes with 
the last two hypotheses.31,33 Further studies are required to ascer-
tain whether the antibiotic-induced changes at the level of micro-
bial composition and function have immediate or long-lasting 
collateral effects and whether they are preventable; this should 
be of practical importance since this phenomenon linked to anti-
biotic therapy may be one of the mechanistic factors involved in 
infancy to adulthood obesity. Indeed, early-life treatment with 
antibiotics altered murine metabolic homeostasis and increased 
adiposity in mice.34
Another interesting result of this study was the high ana-
bolic capacity toward dietary sugars in obese patients. In addi-
tion, compared with lean, obese microbiota have a preferential 
capacity to anabolize polysaccharides containing α-glucose 
and α-arabinofuranose while having a relative lower capacity 
to metabolize α-rhamnose, β-fucose, α-arabinopyranose and 
β-glucose (an essential plant component). Accordingly, it is plau-
sible, that a mechanism that promotes weight gain and insulin 
resistance or type 2 diabetes in obese,35,36 may be the increased 
level of enzymes aimed at the digestion of highly refined car-
bohydrates, particularly α-polyglucoses, the “western diet” 
hypothesis.19 Recently, the role of gut microbiota in the patho-
physiology of insulin resistance and obesity was demonstrated 
because the transfer of lean microbiota increased insulin sensitiv-
ity in male recipients with metabolic syndrome.35 Despite this 
bulk of data, there is no known functional mechanism to explain 
this link. Our data provide for the first time a metabolic connec-
tion between gut microbiota and host glucose metabolism as we 
observed a positive correlation between gut glycosidase activities 
and biochemical parameters such as BMI for all subjects but P1 
(see below) and fasting blood glucose level and HOMA-IR index 
in obese subjects. The sigmoid model proposed for BMI and GH 
activity pose an intriguing question on the causes that trigger gut 
GH anabolic capacity at BMI higher than 24, an event that sig-
nificantly enhance energy extraction from dietary α-polyglucoses. 
Food choices, social components, physical performance and 
were highly deactivated by meaning of the lower expression level 
(2.6- to 117-fold) of proteins assigned to those pathways, com-
pared with FS-0. Other striking differences observed on day 11 
included nucleotide metabolism (average 53-fold lower protein 
expression), oxidative phosphorylation (3.3-fold lower protein 
expression) and the tricarboxylic acid cycle (4.5-fold lower pro-
tein expression) (tables s4 and s5).
Using a similar approach, network models (fig. s3) were cre-
ated for two of the adolescents herein investigated (Obese111 
and LeanCE01) according to their available metaproteome mea-
surements.6 Forty and 38 reactions were found to be potentially 
up and downregulated in obese as compared with lean sub-
jects, respectively; additionally, 14 reactions were only found in 
obese and 8 in lean. The results confirmed that bacterial pro-
tein extracts from the obese had a significant improved contri-
bution of proteins linked to the pentose phosphate metabolism 
(25.3-fold) and the tricarboxylic acid cycle (8.9-fold). To note 
is that both pathways were also significantly upregulated (7.8- 
and 52.3-fold, in the same order) in the subject P1 at the end of 
the antibiotic therapy (day 14) as compared with the admission 
day prior to the antibiotic treatment (table s5). Additionally, the 
fructose and mannose (14.4-fold), galactose (21.2-fold), starch 
and sucrose (31.9-fold) and amino sugar and nucleotide sugar 
(14.0-fold) metabolisms were also upregulated in the obese, in 
agreement with the higher activity of obese GIT for these types 
of sugars (fig. 1b).
Discussion
The results presented here enabled us to gain valuable insights 
into the biochemical and metabolic-wide effects of antibiotic 
usage and obesity in the gut microbiota. The study also allowed 
us to propose presumptive links between these variables. First, 
there were significantly increased rates of sugar metabolism in 
both 14 d β-lactam treated patients and obese, albeit at dif-
ferent levels, which correlated with the strong activation of 
network reactions linked to glycolysis and pentose phosphate 
pathways. Second, as compared with non-treated patients and 
leans, both antibiotic-treated and obese subjects had a less bal-
anced GIT functional environment with significant alteration 
in the hydrolytic capacity of ~40% of all sugars tested. These 
factors all together promote the digestion and energy extraction 
from dietary polysaccharides and the fermentation of their final 
products. As shown earlier,30 these are major factors contribut-
ing to the diversity of human GIT microbiota and its impact on 
host metabolism, metabolic syndrome and obesity. In addition, 
the findings presented here point to an age-independent cor-
relation between GIT glycosidase activity and (1) BMI for ten 
out of 11 subjects investigated and (2) blood glucose levels and 
insulin resistance in obese patients. Finally, our data support the 
hypothesis that antibiotic therapy additionally altered the active 
fraction of enzymes controlling the thickness, composition and 
consistency of the mucin glycans.
The duration of the antibiotic treatment was found to be an 
important factor affecting the activity and stability of the GIT 
carbohydrate metabolism. Although our native microbiota is 
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Figure 3. Correlation between metabolic GIT activity and anthropometric and biochemical parameters. (A) Association between the BMI and total 
glycosidase activity. Note: no correlation was found for P1 (for additional comments see Discussion), and its data are not considered for the regres-
sion. (B) Association between the fasting blood glucose level and total glycosidase activity in obese subjects; inset in (B) represents the association 
between HOMA-IR index28 (calculated by an automatic web calculator; http://www.hcvsociety.org/files/HOMACalc.htm) and total glycosidase activity. 
The mean values for each group of samples were calculated using three independent measurements and according to the method and data described 
in Figure 1.
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of the antidiabetic drug, the in deep consequences of which may 
be further evaluated.
We advocate that biochemically-driven, systems-biology 
approaches15 investigating different antibiotics and subjects with 
different characteristics (defined, for example, by age and clini-
cal and biochemical parameters) and different dietary variations 
and diseases will be required to properly establish the linkage 
between GIT biochemical shifts and human health status accord-
ing to different environmental factors. The fact that the present 
study indicates that biodiversity evenness and richness and pro-
tein abundance and expression may not be taken as indicators of 
metabolic activities, supports the importance of such functional 
analysis. Finally, the results suggest that biochemical data could 
be used as a potential marker for comparative purposes in future 
studies on the Human Microbiome Project.
Materials and Methods
subjects and sampling. Written, informed consent was obtained 
from all of the subjects. After Institutional Review Board (IRB) 
review, this study was exempted from IRB approval. The study 
related to P1 and P2 was approved by the Ethical Board of the 
Medical Faculty of the Christian-Albrecht-University, Kiel, 
Germany. Both patients were admitted to the Department of 
Internal Medicine at the University Hospital Kiel (Germany) 
because of an infected cardiac pacemaker. For P1, antibiotic 
therapy was initiated upon admission with a combined intrave-
nous therapy of ampicillin/sulbactam (2 × 750 mg) and cefazolin 
(3 × 2 g/day) in a single dose and continued with cefazolin alone 
intravenously for the next 14 d.10 For P2, antibiotic therapy was 
initiated upon admission with an intravenous therapy of cefazolin 
(3 × 2 g/day) for seven days and continued with ampicillin/sul-
bactam (2 × 750 mg) for next seven days. FS from both patients, 
who had not taken antibiotics within the previous three months 
and did not present any intestinal disorders, were collected on 
14 d time span.
Clinical examination data of P1 has been described else-
where.10 A clinical examination of P2 identified inflamed skin 
and subcutaneous tissue around the pacemaker, and laboratory 
findings revealed an elevated C-reactive protein level (CRP 
18.1 mg/l; normal value < 8 mg/l) and a full blood count within 
normal ranges. The pacemaker had been placed to treat the 
patient’s atrio-ventricular block III, first diagnosed in 1994. She 
had no further cardiovascular risk factors and did not take any 
regular medication. The patient’s CRP level returned to normal 
within eight days after the beginning of AB therapy.
Fresh FS collected from seven obese (four males and three 
females) and five lean adolescents (two males and three females), 
with ages ranging from 13 to 16 y-old, who did not present any 
intestinal disorders and had not taken antibiotics within the pre-
vious 12 mo, were examined. Subjects were selected according 
to their BMI index [weight (kg)/height (m2)] from the panel 
of adolescents collected during the course of the EVASYON 
study.38 The EVASYON study was designed to develop a mul-
tidisciplinary obesity treatment program that was assessed and 
controlled by pediatric services in Spain. All participants in 
many other possible reasons may underlie this effect. Obviously, 
we are aware that these correlations were determined for a very 
small number of subjects and that thus require further confirma-
tion with a higher set of individuals and conditions. However, 
we believe that the correlations observed support our conclusions 
reasonably well and that it is plausible that the changes in the 
GIT microbiota capacity to metabolize carbohydrates may be an 
origin factor to develop obesity, which in turn may be preventable 
at a higher level than previously thought.
Altogether, the knowledge and the hypotheses generated 
herein lay a foundation for subsequent, systematic research that 
will ultimately enable the design of: (1) personalized diets based 
on actual potential digestibility of dietary polysaccharides to 
regulate weight gain and; (2) intervention strategies at defined 
stages of antibiotic therapies to counterbalance their negative col-
lateral effects toward intestinal mucus barrier. As for (1), it is 
plausible, for instance, that subsequent studies will allow defin-
ing GIT “enzymotypes.” Accordingly, this can help identifying 
sets of missing enzymes and sugar-degrading capacities that are 
needed to stabilize the GIT microbiota and which, for example, 
can be added as prebiotics particularly enriched in specific, miss-
ing enzyme components. This is of particular importance as 
carbohydrates are converted by GIT bacterial communities to a 
variety of organic acids and alcohols.37 As for (2), mucosal pro-
tection therapy could be added as a part of normal therapeutic 
guidelines at define stages.
By resorting on an integrated, multidisciplinary metabolic 
analysis, we mapped and assessed the impact of the activity shifts 
on the GIT metabolism itself. We have contributed to establish 
a biochemical baseline of the metabolic functioning of the gut 
microbiota, through which we have suggested potential biochem-
ical links between antibiotic use and obesity, between anthro-
pometric and biochemical parameters and GIT carbohydrate 
metabolism. However, these results should be seen under the 
light of an explorative study, as there are several limitations that 
prevent us to take definitive conclusions, in particular with regard 
to the links between metabolism dynamics of antibiotic pertur-
bation and obesity. First, we did not examine a separate cohort 
of subjects that would serve as controls to evaluate the effect of 
aging on the GIT biochemical environment structure. Second, 
we only measured the effect of antibiotics without considering 
the diet of each of the subjects investigated. It is unknown to 
what degree aging and alterations of diet components correlate 
with the biological functions herein examined. However, we 
believe that the impact of aging and diet on our results would be 
comparatively minor because we did not find significant inter-
personal variations in hydrolytic rates within each of the three 
different groups of unrelated individuals investigated; also, the 
fact that all adolescents and one adult (P2) with similar BMI do 
have similar total glycosidase activity (independently of the age 
and diet) agree with this hypothesis. Third, we should stress the 
attention to the fact that no correlation between GIT glycosidase 
activity and BMI was found for P1; to note is that subject P1 is 
a non-insulin-dependent diabetes mellitus patient daily treated 
with glimepiride (together with amlodipine, ramipril, hydrochlo-
rothiazide and Marcumar).10 This suggests additional side effects 
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Protein Extraction Reagent (Novagen, Darmstadt, Germany) for 
30 min at 4°C, with further disruption by sonication (using a 
pin Sonicator® 3000; Misonix) for 2.5 min (10 W) on ice (5 
cycles × 0.5 min). The extracts were then centrifuged for 10 
min at 12,000 g to separate cell debris and intact cells and the 
supernatants carefully aspirated (to avoid disturbing the pellet) 
and transferred to a new tube. Proteins were stored at −80°C at a 
~0.22 mg/ml concentration until use.
Glycosidase activity was quantified in triplicates in 96-well 
plates using a BioTek Synergy HT spectrophotometer in a col-
orimetric assay with a set of 23 structurally diverse sugars (as 
p-nitrophenol [pNP] derivatives, all from Sigma Chemical Co.) 
EVASYON respect the following international conventions and 
declarations.38
The anthropometric, clinical and biochemical data are shown 
in table s1.
biochemical experimental setting. Fresh stool samples were 
collected from each subject, frozen immediately and stored 
at −80°C until further processing. Protein extracts were iso-
lated, as described previously.6,10 Briefly, FS were resuspended 
in phosphate-buffered saline solution (PBS). The samples were 
then centrifuged at 2,000 g at 4°C for 2 min to remove fecal 
debris. The supernatant was centrifuged at 13,000 g for 5 min 
to pellet the bacterial cells, which were lysed in BugBuster® 
Figure 4. Relative abundance and expression levels of GH-like enzymes (referred as CAZymes, carbohydrate active enzymes) and other enzymes 
(proteins with EC numbers) compared with the total amount of protein recovered from each of the shotgun metaproteomes of the GIT microbiota of 
patient P1. The results are the average of the shotgun metaproteome measurements from two independent technical replicates per sample.10
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represented in the entire metabolic network.41,42 Customized 
computer programs written in R27 and Perl (http://www.perl.
org/) were used to obtain enzyme information from local copies 
of KEGG. To explore the variation in the full metabolic network 
that represented the metabolic activities of the microbiome, we 
pooled them to ensure that the same EC code originating from 
different organisms in each of the considered samples was con-
sidered linked to the same metabolic function. This information 
was further integrated with a generic metabolic map, which was 
constructed using information from KEGG,41,42 which provided 
an overview of the complete metabolism of the biological system.
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that represented the core structure of common glycans and under 
previously described conditions,39 with minor modifications. 
Briefly, reactions contained 4.0 μg total protein and 1 mg/ml 
sugar substrate (from a 10-mg/ml stock solution) in a 20-mM 
glycine buffer (pH 9.0, T = 30°C in a final volume of 150 μl). 
Reactions were followed every 10 min by measuring the release of 
pNP at 410 nm for 130 min. In all cases, one unit (U) of enzyme 
activity was defined as the amount of protein producing 1 μmol 
of reducing sugars for 1 min under the assay conditions.
proteome-scale metabolic reconstruction. Available network 
reconstructions in the literature are generally organism-specific. 
Genome-scale metabolic networks provide a more accurate 
description of the metabolic processes of specific organisms, typi-
cally including manually curated physiological information as 
well as in silico algorithmic refinements. Apart from the reactions 
and their associated information (reversibility, compartment, EC 
number and genes), additional experimental information may be 
involved. Accordingly, metabolic reconstruction typically starts 
from an annotated genome, which is then integrated with reac-
tion databases and reported physiological evidence, as well as 
gene transcript levels or protein expression values, to produce a 
functional computational model. In our case, the reconstruction 
was slightly different because we aimed to reconstruct the entire 
gut metabolic network, where multiple proteins from multiple 
organisms are co-expressed. Herein we used the expression val-
ues of the set of proteins that were unambiguously quantified in 
the shotgun metaproteomes in the same set of samples used for 
activity tests (P1, Obese111 and LeanCE01),6,10 to produce meta-
bolic reconstructions of the entire gut metabolic network, where 
multiple proteins from multiple organisms are co-expressed. The 
enzyme commission number (EC number) was used as a numeri-
cal classification scheme for enzymes based on the metabolic reac-
tions they catalyze, with each EC class exclusively defining the 
function performed by the enzyme.40 EC numbers in this analysis 
are exclusively used to refer to specific enzymes. Using appro-
priate bioinformatics tools, the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) was used to obtain the names and EC 
codes of the enzymes corresponding to the metabolic reactions 
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